Evogene Partners with Google Cloud to Build AI Model for Small Molecule Discovery
Computational biology firm Evogene Ltd. has partnered with Google Cloud to develop an advanced AI foundation model for small molecule design, building on the recent integration of Evogene’s ChemPass AI platform with Google Cloud’s Vertex AI and Compute Engine infrastructure. This collaboration aims to expand ChemPass AI’s capabilities, accelerating molecular discovery in sectors such as pharmaceuticals and agriculture.
The foundation model, trained on a dataset of roughly 40 billion molecular structures, is designed to generate and optimize novel molecules, streamlining candidate identification for drug discovery and crop protection. Leveraging Google Cloud’s scalable GPU power and storage solutions, the model is expected to improve the speed and accuracy of R&D processes across life-science applications.
In the pharmaceutical field, this model could reduce costs and shorten discovery timelines by enhancing the selection of promising candidates. For agriculture, it enables more sustainable approaches to crop protection and food security, while also extending to other industries that benefit from innovative molecular structures.
See also: The Explosion of Therapeutic Modalities: Small Molecules, Biologics, and Everything in Between
Evogene’s ChemPass AI forms part of a broader suite of proprietary technologies applied within its subsidiaries, including Lavie Bio Ltd. in agricultural solutions and Biomica Ltd. in microbiome-based therapeutics. These initiatives reflect Evogene’s goal of expanding computational biology applications to address pressing challenges in drug development, sustainable agriculture, and environmental sustainability.
Topics: AI & Digital
